Muñoz, J., Chavez, J. C., Westin, J., Bachy, E., Morillo, D., Joergensen, J. M., Perini, G. F., Costa, A., Rao, P., Marsousi, N., Yang, G., Sudhindra, A., Pourdehnad, M., Carrancio-Anton, S., Voestch, J., Perna, S. K., Michot, J. (2026). Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD ± rituximab (R) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Long-term follow-up (f/u) of the phase (Ph) 1/2 CC-99282-NHL-001 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e19046